Management of relapsed multiple myeloma after autologous stem cell transplant

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L. McCarthy

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Autologous stem cell transplantation (ASCT) remains a standard of care for multiple myeloma patients who are eligible to receive high-dose therapy, recognizing that the optimal timing and integration of this approach is now under study in a number of randomized trials. Despite the improved response rates with induction therapy consisting of immunomodulatory drugs and/or proteasome inhibitors, as well as the increasing use of post-ASCT maintenance therapy, most myeloma patients relapse and die of their disease. Here we discuss the options for managing post-ASCT relapse, including the role of various salvage regimens in the setting of relapsed and refractory myeloma, salvage ASCT, and salvage allogeneic SCT.

Original languageEnglish (US)
Pages (from-to)793-798
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Issue number5
StatePublished - May 1 2015
Externally publishedYes


  • Monoclonal antibody
  • Multiple myeloma salvage autologous stem cell transplant
  • Relapsed/refractory
  • Salvage allogenic stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Management of relapsed multiple myeloma after autologous stem cell transplant'. Together they form a unique fingerprint.

Cite this